{"title":"Innovative therapy in clinical practice: Ethical perspective from China.","authors":"Xiaonan Wang, Jichao Wang, Kun Li, Xiaomei Zhai","doi":"10.1111/dewb.12480","DOIUrl":null,"url":null,"abstract":"<p><p>Innovative therapy, as a new paradigm of medical intervention deviating from standard routine practice, prioritizes the best interests of patients, offering alternative therapeutic pathways where standard treatments fail. In China, their application is increasing alongside advancements in medical technology. However, innovative therapy poses various ethical challenges in clinical settings, including misconceptions of being viewed as research rather than therapy, benefit-risk assessment complexities, conflicts of interest, and barriers to the development of effective regulatory strategies. This paper elucidates the concept of innovative therapy and critically examines these challenges within the Chinese clinical context, emphasizing patients' best interests. It proposes establishing guidelines and a comprehensive, adaptable regulatory framework to address the unmet healthcare-related needs of individual patients and mitigate risks. Engaging in these discussions provides some ethical insights from China on innovative therapy, serving as a reference for fostering the development and responsible utilization of innovative therapy.</p>","PeriodicalId":50590,"journal":{"name":"Developing World Bioethics","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developing World Bioethics","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1111/dewb.12480","RegionNum":3,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0
Abstract
Innovative therapy, as a new paradigm of medical intervention deviating from standard routine practice, prioritizes the best interests of patients, offering alternative therapeutic pathways where standard treatments fail. In China, their application is increasing alongside advancements in medical technology. However, innovative therapy poses various ethical challenges in clinical settings, including misconceptions of being viewed as research rather than therapy, benefit-risk assessment complexities, conflicts of interest, and barriers to the development of effective regulatory strategies. This paper elucidates the concept of innovative therapy and critically examines these challenges within the Chinese clinical context, emphasizing patients' best interests. It proposes establishing guidelines and a comprehensive, adaptable regulatory framework to address the unmet healthcare-related needs of individual patients and mitigate risks. Engaging in these discussions provides some ethical insights from China on innovative therapy, serving as a reference for fostering the development and responsible utilization of innovative therapy.
期刊介绍:
Developing World Bioethics provides long needed case studies, teaching materials, news in brief, and legal backgrounds to bioethics scholars and students in developing and developed countries alike. This companion journal to Bioethics also features high-quality peer reviewed original articles. It is edited by well-known bioethicists who are working in developing countries, yet it will also be open to contributions and commentary from developed countries'' authors.
Developing World Bioethics is the only journal in the field dedicated exclusively to developing countries'' bioethics issues. The journal is an essential resource for all those concerned about bioethical issues in the developing world. Members of Ethics Committees in developing countries will highly value a special section dedicated to their work.